BlackRock
LYEL icon

BlackRock’s Lyell Immunopharma LYEL Stock Holding History

BlackRock’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
724,342
+532,522
+278% +$9.64M ﹤0.01% 3670
2026
Q1 		$3.85M Buy
191,820
+9,983
+5% +$233K ﹤0.01% 3933
2025
Q4 		$5.6M Buy
181,837
+5,031
+3% +$113K ﹤0.01% 3788
2025
Q3 		$2.87M Buy
176,806
+31,947
+22% +$365K ﹤0.01% 3984
2025
Q2 		$1.28M Sell
144,859
-491,220
-77% -$4.48M ﹤0.01% 4175
2025
Q1 		$6.84M Sell
636,079
-27,214
-4% -$333K ﹤0.01% 3503
2024
Q4 		$8.49M Sell
663,293
-24,061
-4% -$477K ﹤0.01% 3510
2024
Q3 		$19M Buy
687,354
+12,597
+2% +$370K ﹤0.01% 3080
2024
Q2 		$19.6M Sell
674,757
-19,874
-3% -$946K ﹤0.01% 2999
2024
Q1 		$31M Sell
694,631
-20,480
-3% -$877K ﹤0.01% 2736
2023
Q4 		$27.7M Buy
715,111
+44,099
+7% +$1.59M ﹤0.01% 2818
2023
Q3 		$19.7M Buy
671,012
+16,922
+3% +$804K ﹤0.01% 2950
2023
Q2 		$41.6M Buy
654,090
+37,233
+6% +$2.06M ﹤0.01% 2600
2023
Q1 		$29.1M Buy
616,857
+8,406
+1% +$450K ﹤0.01% 2776
2022
Q4 		$42.2M Buy
608,451
+22,096
+4% +$2.19M ﹤0.01% 2582
2022
Q3 		$86M Buy
586,355
+86,369
+17% +$11.7M ﹤0.01% 2067
2022
Q2 		$65.2M Buy
499,986
+109,511
+28% +$11.2M ﹤0.01% 2307
2022
Q1 		$39.4M Buy
390,475
+290,502
+291% +$35.2M ﹤0.01% 2718
2021
Q4 		$15.5M Buy
99,973
+28,628
+40% +$6.38M ﹤0.01% 3423
2021
Q3 		$21.1M Buy
71,345
+58,965
+476% +$17.7M ﹤0.01% 3241
2021
Q2 		$4.02M Buy
+12,380
New +$4.06M ﹤0.01% 3971

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock's LYEL Position: Q2 2026 in Review

BlackRock increased its Lyell Immunopharma (LYEL) stake by 278% in Q2 2026, buying an estimated $9.64M and bringing the position to 724,342 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

BlackRock first reported a position in LYEL in Q2 2021 and has held it in 21 quarters since. The position peaked at $86M in Q3 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • BlackRock held 724,342 shares of Lyell Immunopharma worth $10.2M as of Q2 2026.
  • BlackRock bought 532,522 Lyell Immunopharma shares in Q2 2026, an estimated $9.64M.
  • Lyell Immunopharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3670 holding.
  • BlackRock first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 21 quarters since.
  • BlackRock's Lyell Immunopharma position peaked at $86M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.